Login to Your Account



Other News To Note


Tuesday, February 1, 2011
Pfizer Inc., of New York, completed its tender offer for Bristol, Tenn.-based King Pharmaceuticals Inc. The firms agreed to an acquisition deal in October that valued King at $14.25 per share, or about $3.6 billion.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription